CRISPR

Exclusive Jason Mast

STAT Plus: Feng Zhang’s year-old CRISPR delivery startup Aera lays off quarter of staff

The Readout Damian Garde

STAT Plus: Why CG Oncology will be the first test of 2024’s IPO waters

Biotech Megan Molteni

STAT Plus: 3 CRISPR advances to watch in 2024

Morning Rounds Elizabeth Cooney

Morning Rounds: Our newsroom’s favorite stories of 2023

Morning Rounds Elizabeth Cooney

Morning Rounds: Why health care costs are nearly a fifth of the GDP

The Readout Damian Garde

STAT Plus: BioMarin appeases an activist

Health Jason Mast

After ‘SNL’ skit on sickle cell CRISPR therapy, advocates cite errors and stereotypes

Biotech Damian Garde

STAT Plus: 3 trends to watch in biotech in 2024

Biotech Andrew Joseph

STAT Plus: European regulators endorse Casgevy, paving way for approval of CRISPR-based therapy

The Readout Damian Garde

STAT Plus: Is it time to worry about Moderna?

Biotech Jason Mast

STAT Plus: After decade-long dispute over CRISPR-Cas9, Editas strikes deal with Vertex to cash in

The Readout Damian Garde

STAT Plus: A plot to solve the ‘whack-a-mole’ of drug discovery

Biotech Jason Mast

STAT Plus: Could sickle cell someday be treated not with CRISPR, but with a pill?

First Opinion Robert Brodsky

New sickle cell disease CRISPR treatments can’t make up for the shortage of adult hematologists

The Readout Theresa Gaffney

Morning Rounds: Preterm birth rates vary across the U.S., with the highest in the Southeast

Biotech Jonathan Wosen

STAT Plus: Historic approval of sickle cell gene therapies met with cautious optimism by experts at ASH

Biotech Adam Feuerstein

STAT Plus: A Q&A with the CEO of CRISPR Therapeutics on a historic approval and the road ahead

Biotech Adam Feuerstein

STAT Plus: In historic decision, FDA approves a CRISPR-based medicine for treatment of sickle cell disease

Morning Rounds Elizabeth Cooney

STAT Plus: Morning Rounds: 3D-printed organs, antimicrobial resistance in Ukraine, and other major health stories of the day

The Readout Meghana Keshavan

CRISPR is about to make history. Here’s the 5-minute rundown of what to expect

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

CRISPR history, biotech struggles, & a big week for deals

Morning Rounds Elizabeth Cooney

STAT Plus: Morning Rounds: Couples share high blood pressure, and other health stories you should read today

Morning Rounds Theresa Gaffney

STAT Plus: STAT Morning Rounds: Six health news stories you need to start your day

The Readout Meghana Keshavan

STAT Plus: Novartis is building a new radioligand plant in China

Biotech Jason Mast

STAT Plus: How sickle cell became the first disease treated by CRISPR

The Readout Meghana Keshavan

STAT Plus: A new algorithm unveils CRISPR ‘treasure trove’

The Readout Meghana Keshavan

STAT Plus: Merck cough drug doesn’t pass panel scrutiny

Exclusive Matthew Herper

STAT Plus: CRISPR’s pioneers reflect on the first gene-editing treatment

The Readout Damian Garde

STAT Plus: The return of biotech’s “bump factor” amid an economic downturn